drugset / Trial / NCT04732845
Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if it is possible to treat relapsed or refractory lymphoid malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia) with a new type of T cell-based immunotherapy (therapy that uses the immune system to treat the cancer).
Timeline
- Start
- 2021-04-26
- Primary completion
- 2025-09-01
- Completion
- 2039-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fully human anti CD19 CAR-T Cell | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | Fully human anti CD19 CAR-T Cell | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | Fully human anti CD19 CAR-T Cell | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | Fully human anti CD19 CAR-T Cell | Cell therapy | 2e+06 cells/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 60 mg/kg | — |
| Background | Fludarabine | Small molecule | 25 mg/m2 | — |